Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.
MorphoSys marches ahead with plans to file myelofibrosis drug despite mixed PhIII results
MorphoSys is declaring success on a Phase III study involving the key cancer drug from its $1.7 billion buyout of Constellation, but a secondary endpoint
November 22, 2023